Thus, by decreasing Treg numbers systemically, CDK4/6 therapy likely supports increased priming of tumor-antigen specific T cells in tumor draining lymph nodes and their subsequent expansion in the tumor microenvironment (25–27). This evidence concerns the gene CDK4 and neoplasm.